Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Price & Analysis
152 Followers
GPCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.79 - $75.02
Previous Close$39.29
Volume423.23K
Average Volume (3M)586.86K
Market Cap
$1.83B
Enterprise Value$1.37B
Total Cash (Recent Filing)$467.32M
Total Debt (Recent Filing)$5.45M
Price to Earnings (P/E)-15.7
Beta1.06
Next Earnings
May 09, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.51
Shares Outstanding46,598,041
10 Day Avg. Volume504,522
30 Day Avg. Volume586,858
Standard Deviation0.30
R-Squared0.25
Alpha0.13
Financial Highlights & Ratios
Price to Book (P/B)4.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-21.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-15.37
Forecast
1Y Price Target
$80.50Price Target Upside104.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Structure Therapeutics, Inc. Sponsored ADR News
Bulls Say, Bears Say
Bulls Say
Investment OpportunityAnalyst believes GSBR-1290's safety and efficacy profile positions it as a competitive GLP-1R agonist, offering investment opportunity if subsequent trials yield better results.
Market PotentialThe total addressable market in the US for obesity therapies is approximately 176 million adults, indicating a large potential market for treatments.
Product DifferentiationStructure's oral GLP-1 is differentiated in a market with high unmet need for more convenient and cheaper options.
Bears Say
Clinical Trial ResultsGSBR-1290 weight loss disappointed in diabetics compared to LLY’s orforglipron.
Drug EfficacyIf the 12-week weight loss results do not approach competitor orforglipron's performance without liver toxicity concerns, it may negatively impact the stock.
Financial StabilityThe company has an annualized cash burn of $224.0 million, which indicates the company's current rate of spending.
---
Ownership Overview
24.31% Insiders
35.59% Mutual Funds
1.99% Other Institutional Investors
38.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $21.79 and its highest was $75.02 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Currently, no data Available
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is May 09, 2024 which is in 2 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Mar 08, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.186 by $0.036.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -$0.21.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 46,598,040 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.186. Following the earnings report the stock price went up 2.36%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Among the largest hedge funds holding Structure Therapeutics, Inc. Sponsored ADR’s share is Driehaus Capital Management LLC. It holds Structure Therapeutics, Inc. Sponsored ADR’s shares valued at 106M.
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.50 (104.89% Upside)
$80.50 (104.89% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 866.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.02%
12-Months-Change
Fundamentals
Return on Equity
-33.29%
Trailing 12-Months
Asset Growth
392.63%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
---
GPCR Stock 12 Months Forecast
Average Price Target
$80.50
▲(104.89% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+15.08%
assigned a buy rating 15 days ago
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +15.08% per trade.
---